Other languages Solasia Pharma K.K.

Equities

4597

JP3436500007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 EDT			5-day change	1st Jan Change
27 ^JPY	0.00%		+3.85%	-40.00%

03-04	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI
02-16	Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	12-28
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains	11-13
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	11-13
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-10
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	23-05-15
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program	23-03-20
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023	23-02-14
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study	22-11-27
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-25
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.	22-11-21
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-14
Solasia Announces Summary of SP-04 PledOx Development Status	22-09-05
Solasia gibt Einführung von Darvias® in Japan bekannt	22-08-22
Solasia anuncia el lanzamiento de Darvias® en Japón	22-08-22
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-08-15
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)	22-08-03
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX).	22-07-07
Solasia Pharma: DARVIAS® als Injektion mit 135 mg (generischer Name: DARINAPARSIN/Entwicklungscode: SP-02) in Japan zugelassen	22-06-20
Solasia Pharma: DARVIAS® Inyección de 135 mg (Nombre genérico: DARINAPARSINA /Código de desarrollo: SP-02) Aprobado en Japón	22-06-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Solasia Pharma K.K.

Equities

4597

JP3436500007

Other languages

Filters